Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced encouraging results from a series of preclinical studies evaluating Livatag® interest for pancreatic cancer.
Livatag® (doxorubicine Transdrug™, a nanoparticle formulation of doxorubicin) is currently being evaluated clinically as a monotherapy in a Phase III ReLive trial for second-line advanced hepatocellular carcinoma (HCC). More than 90% of expected patients have been randomized and study preliminary data are expected mid-2017.
In parallel, the company has initiated an exploratory preclinical evaluation program of Livatag® for new indications, such as pancreatic cancer, which is part of Onxeo’s strategic efforts to capitalize on the specific benefits of Livatag® (doxorubicin Transdrug™, a nanoparticle formulation of doxorubicin) and the acquired knowledge of its mechanism of action to provide potential new therapeutic options for patients with unmet medical needs and further generate additional value for shareholders with this promising compound.
A first set of preclinical studies has been performed and confirmed several key advantages of Livatag® versus free doxorubicin:
Following the initial mechanisitic and pharmacokinetic/pharmacodynamic data, the company intiated a study plan to assess the effect of Livatag® in comparison with current standard treatments, either in monotherapy or in combination to assess how these first data might translate into the clinical setting to validate the potential interest of Livatag® in this indication. In a mouse syngeneic pancreatic cancer model, Livatag® as a monotherapy proved to be as effective or more effective than current therapies, including chemotherapies gemcitabine, paclitaxel, and erlotinib. In addition, the study demonstrated that Livatag® combines well with these three therapies, showing good tolerance and exhibiting supra-additive efficacy in all combinations compared to each agent alone.
Graham Dixon, PhD, Chief Scientific Officer of Onxeo, commented, “The results from these preclinical studies of Livatag® in pancreatic cancer have generated promising potential for the drug in this indication. These exploratory data on the mechanistic rational of Livatag® for pancreatic cancer, supported by the outcomes in comparison with clinical standards, provides a strong rationale to fully explore the opportunity to further develop Livatag® in this indication. We are also highly encouraged by the supra-additive effects observed in combination with checkpoint inhibitors in these animal models, which we will further explore.”